Portable Artificial Pancreas Applied for Youth and Adolescents

Diabetes Mellitus, Type 1 Clinical Trial

— PAPAYA 1  

Official title:

Portable Artificial Pancreas Applied for Youth and Adolescents

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05543850
• Other study ID #: NL79829.000.22
• Status: Completed
• Phase: N/A
• Start date: October 28, 2022
• Est. completion date: May 19, 2023

Study information

• Verified date: August 2023
• Source: Inreda Diabetic B.V.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the performance of a bi-hormonal reactive closed-loop system in adolscents with type 1 diabetes mellitus. The percentage of time spent in the target range (3.9-10.0 mmol/L) is the main outcome and will be compared between the bi-hormonal closed-loop system and the current treatment of the patients. Also, safety parameters, pharmacodynamics and patient reported outcomes (expectations, trust and treatment satisfaction scores) are compared.

This study is a monocenter, randomized, cross-over trial with 20 subjects. The subjects will be randomized to receive either the open-loop therapy or the closed-loop therapy for the first two-week study period and switch to the alternate treatment with at least two weeks in between.

Description:

Background of the study:

Inreda Diabetic B.V. (Goor, The Netherlands) developed a bi-hormonal reactive closed loop system to automate glucose regulation (artificial pancreas; AP) in patients with diabetes mellitus type 1. In previous studies, we tested the performance and safety of this bi-hormonal closed-loop system in an outpatient setting in patients with type 1 diabetes mellitus (T1DM) for a duration up to 2 weeks, leading to CE-marking of the system. The device is currently intended for insulin-dependent adult patients with diabetes. However, there is great need to improve glycaemic control in youth and adolescents with diabetes.

Objective of the study:

The main objective of this study is to determine the performance of the closed-loop system in adolescents with T1DM. Secondary objectives include: to assess the safety of the closed-loop system; to determine the time that the closed-loop algorithm is active; and to assess expectations and treatment satisfaction of the closed-loop system.

Study design:

This study is a monocenter randomized cross-over trial.

Study population:

The study population will comprise 20 patients with T1DM, between 12 and 18 years old, not having impaired awareness of hypoglycaemia, and who are treated with insulin therapy for at least 6 months. Patients receiving treatment with multiple daily injections (MDI) or continuous subcutaneous insulin injections (CSII), and in addition glucose monitoring using self-monitored blood glucose (SMBG), flash glucose monitoring (FGM) or continuous glucose monitoring (CGM) are included into the study.

Intervention:

The intervention includes 2 weeks of closed-loop control with the artificial pancreas (AP) of Inreda Diabetic. The device uses 2 subcutaneous glucose sensors, 2 subcutaneous infusion sets, and incorporates 2 pumps and a reactive closed-loop algorithm. During 4-6 days before the intervention the patients receive training on the use of the closed-loop system and will start using the device under close supervision. The control arm (open loop treatment) consists of the patient's standard therapy at home for 2 weeks.

Main study parameters/endpoints:

Main study parameter is the percentage of time spent in the target range (3.9-10.0 mmol/L), which will be compared between the open and closed-loop periods for each patient.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: May 19, 2023
• Est. primary completion date: May 19, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years to 18 Years

Eligibility

Inclusion Criteria:

• Diagnosed with type 1 diabetes mellitus

• Twelve to eighteen years old;

• Treated with insulin therapy for at least 6 months;

• Willing and able to sign informed consent or to assent to study participation.

Exclusion Criteria:

• Impaired awareness of hypoglycaemia (score = 4) according to Gold and/or Clarke questionnaire[6,7];

• BMI = 35 kg/m2;

• Pregnancy and/or breastfeeding;

• HbA1c > 97 mmol/mol (11.0%);

• Use of acetaminophen (paracetamol) during the open loop or closed-loop period,as this may influence the sensor glucose measurements;

• Limited ability to see, hear or feel the alarm signals of the closed-loop system;

• Unwillingness to act in response to the alarm signals;

• Living alone during the night during the closed-loop period (the patient may ask someone to stay over temporarily);

• Expected poor internet connectivity regarding 24/7 tele monitoring;

• Any condition that the local investigator feels would interfere with trial participation or evaluation of the results.

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 1

Intervention

Device:
• Bi-hormonal closed-loop control
During bi-hormonal closed-loop control insulin and glucagon are administered to the developed closed-loop algorithm. Aditionally, patients will wear a blinded Dexcom G6 for data collection during the closed loop period.
• Open-loop control
During open-loop control the patients will use their usual diabetes therapy. Aditionally, patients will wear a blinded Dexcom G6 for data collection during the open loop period.

Locations

Country	Name	City	State
Netherlands	Rijnstate Ziekenhuis	Arnhem	Gelderland

Sponsors (4)

Lead Sponsor	Collaborator
Inreda Diabetic B.V.	Kinder Diabetes Centrum Nijmegen, Rijnstate ziekenhuis, Stichting Robopump

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Gender	Gender (M/F)	Baseline
Other	Weight	Weight in kg	Baseline
Other	Length	Length in cm	Baseline
Other	HbA1c plasma concentration	HbA1c plasma concentration in mmol/mol	Baseline
Other	Current medication use	List of medication names and corresponding dosages	Baseline
Other	Insulin dose	Daily average of insulin in units	2 weeks
Other	Glucagon dose	Daily average of glucagon in units	2 weeks
Primary	Time in range	The proportion of time spent in the range of 3.9-10.0 mmol/L in %	2 weeks
Secondary	Time in hypoglycemia 1	The proportion of time spent in hypoglycemia (<3.9 mmol/L) in %	2 weeks
Secondary	Time in hypoglycemia 2	The proportion of time spent in hypoglycemia (<3.0 mmol/L) in %	2 weeks
Secondary	Time in hyperglycemia 1	The proportion of time spent in hyperglycemia (>10.0 mmol/L) in %	2 weeks
Secondary	Time in hyperglycemia 2	The proportion of time spent in hyperglycemia (>13.9 mmol/L) in %	2 weeks
Secondary	Mean glucose concentration	Mean glucose concentration in mmol/L	2 weeks
Secondary	Median glucose concentration	Median glucose concentration in mmol/L	2 weeks
Secondary	Glycemic variability - Coefficient of variation	Coefficient of variation (standard deviation divided by the mean) in %	2 weeks
Secondary	Glycemic variability - Interquartile range	Interquartile range in mmol/L	2 weeks
Secondary	Mean glucose concentration during the day	Mean glucose concentration in mmol/L during the day (6AM - 12PM)	2 weeks
Secondary	Mean glucose concentration during the night (12PM - 6AM)	Mean glucose concentration in mmol/L during the night (12PM - 6AM)	2 weeks
Secondary	Median glucose concentration during the day (6AM - 12PM)	Median glucose concentration in mmol/L during the day (6AM - 12PM)	2 weeks
Secondary	Median glucose concentration during the night (12PM - 6AM)	Median glucose concentration in mmol/L during the night (12PM - 6AM)	2 weeks
Secondary	Time spent in hypoglycemia during the night	Time spent in hypoglycemia (<3.9 mmol/L) during the night (12PM - 6AM) in %	2 weeks
Secondary	Time spent in hyperglycemia during the night	Time spent in hyperglycemia (>10.0 mmol/L) during the night (12PM - 6AM) in %	2 weeks
Secondary	Time spent in euglycemia during the night	Time spent in euglycemia (<3.9 mmol/L and <10 mmol/L) during the night (12PM - 6AM) in %	2 weeks
Secondary	Time spent in hypoglycemia during the day	Time spent in hypoglycemia (<3.9 mmol/L) during the day (6AM - 12PM) in %	2 weeks
Secondary	Time spent in hyperglycemia during the day	Time spent in hyperglycemia (>10.0 mmol/L) during the day (6AM - 12PM) in %	2 weeks
Secondary	Time spent in euglycemia during the day	Time spent in euglycemia (<3.9 mmol/L and <10 mmol/L) during the day (6AM - 12PM) in %	2 weeks
Secondary	Algorithm active time	Time that the closed-loop algorithm is active in %	2 weeks
Secondary	Expectations	INSPIRE questionnaire (only for closed loop)	2 weeks
Secondary	Trust	TAS questionnaire (only for closed loop)	2 weeks
Secondary	Satisfaction	DTSQ questionnaire (for open loop and closed loop)	2 weeks